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Hemodynamic responses to vasodilators are commonly
assessed when starting long-term vasodilator treatment
in patients with chronic left ventricular failure, although
the relation between short- and long-term responses is
not established. Thus, short- and long-term hemody-
namic responses to placebo and vasodilators (isosorbide
dinitrate, minoxidil and enalapril or captopril) were
measured and long-term clinical efficacy was assessed
by changes in exercise capacity after 1 to 5 months of
vasodilator administration (plus digitalis and diuretic
agents) in 46 patients with New York Heart Association
fun~tional class II to IV heart failure caused by cardio-
myopathy. There were no significant changes in hemo-
dynamics or exercise capacity during placebo treatment.
After initial doses and during long-term administration
of vasodilator drugs, hemodynamics were significantly
improved. After long-term vasodilator treatment, max-
imal oxygen uptake during exercise increased by 2.9 ±
5.7 ml/min per kg from a control value of 14.1 ± 5.6
The widespread use of vasodilator agents in the management
of congestive heart failure is based largely on the well doc-
umented hemodynamic efficacy of these agents (I ,2). Whereas
hemodynamic measurements are of clear value in catego-
rizing the actions of specific drugs, there is no proof that
From the Cardiovascular Section, Veterans Administration Medical
Center and The Hospital of the University of Pennsylvania, Philadelphia.
Pennsylvania and the Cardiovascular Division. Veterans Administration
Medical Center and University of Arkansas for Medical Sciences, Little
Rock, Arkansas. This study was supported in part by a grant from the
Medical Research Service of the Veterans Administration. Washington.
D.C. This paper was presented in part at the annual scientific sessions of
the American College of Cardiology. New Orleans. Louisiana. March,
1983. Manuscript received August 29, 1983; revised manuscript received
December 13, 1983, accepted December 21, 1983.
*Current address: Veterans Administration Medical Center, University
and Woodland Avenues, Philadelphia, Pennsylvania 19104.
Address for reprints: Joseph A. Franciosa, MD, Cardiovascular Di-
vision, University of Arkansas for Medical Sciences, 4301 West Markham
Street, Mail Slot 532, Little Rock, Arkansas 72205.
© 1984 by the American College of Cardiology
ml/min per kg (p < 0.01), and exercise duration also
increased by 1.8 ± 3.5 minutes (p < 0.01). Changes in
maximal oxygen uptake, however, did not correlate with
short-term changes in pulmonary wedge pressure (cor-
relation coefficient [r] = - 0.14), cardiac index (r =
- 0.01) or systemic vascular resistance (r = - 0.20).
Long-term hemodynamic changes also failed to correlate
with changes in exercise capacity. Baseline hemody-
namics, cardiac dimensions and left ventricular ejection
fraction before vasodilator administration all failed to
correlate with baseline exercise capacity or with long-
term changes in exercise capacity.
Thus, hemodynamic measurements at initiation or
during follow-up of vasodilator therapy do not relate to
long-term clinical efficacy assessed by exercise capacity
in patients with chronic left ventricular failure. There-
fore, the rationale for making invasive hemodynamic
measurements before initiating long-term vasodilator
therapy for heart failure is questioned.
hemodynamic responses to initial doses of vasodilators are
related to the long-term efficacy of these agents in patients
with chronic congestive heart failure. Furthermore, hemo-
dynamics and left ventricular function are usually assessed
at rest, but measurements at rest do not correlate with the
functional capacity of patients with congestive heart failure
(3-5). Whether pre-drug baseline measurements help pre-
dict long-term responses to therapy is also unknown. Despite
these considerations, it has been suggested (6,7) that selec-
tion and dose titration of vasodilators be based on acute
hemodynamic responses to these drugs. Such an approach
usually requires costly hospitalization of patients for the
performance of invasive hemodynamic studies to initiate
long-term vasodilator therapy. The present study was de-
signed to test the validity of this practice. We measured
hemodynamics before and after initial doses of vasodilator
drugs, and examined the relation between these measure-
ments and the subsequent long-term effects of vasodilators
in patients with chronic left ventricular failure.
0735-1097/84/$3.00
1522 FRANCIOSA ET AL.
VASODILATORS IN HEART FAILURE
JACC Vol. 3, No.6
June 1984:1521~30
Methods
Study patients. Studies were performed in 47 men with
congestive heart failure caused by ischemic heart disease or
primary myocardial disease. Ischemic heart disease was di-
agnosed from a history of documented acute myocardial
infarction or a demonstration of obstructive coronary artery
disease by coronary arteriography. Primary myocardial dis-
ease was diagnosed when no other cause of heart failure
was apparent. Patients with primary pulmonary disease,
primary valvular heart disease or acute myocardial infarction
within the preceding 3 months were excluded. Patients whose
exercise ability was limited by angina pectoris or any cause
other than fatigue or dyspnea were also excluded. Patients
were required to have symptoms of exertional dyspnea or
fatigue attributable to cardiac disease for at least 3 months
while being treated with digitalis and diuretic drugs. Ad-
ditional selection criteria required objective evidence of left
ventricular dysfunction manifested as one of the following:
left ventricular internal end-diastolic dimension greater than
2.7 cm/m2 by echocardiography; cardiothoracic ratio greater
than 50% by chest X-ray film and left ventricular ejection
fraction less than 46% by radionuclide angiography. Patients
meeting these initial screening criteria gave written informed
consent; the consent form and study protocol were approved
by the local Human Studies Committees.
Hemodynamic study. Consenting patients were then
brought to a special procedure room adjacent to the medical
intensive care unit for baseline hemodynamic and exercise
evaluation. Vasodilator therapy was discontinued at least
72 hours before hemodynamic studies. Diuretic drugs were
withheld on the day of study, but maintenance digoxin doses
were administered. Right heart catheterization was per-
formed using a triple lumen Swan-Ganz thermistor-equipped
catheter, which was inserted percutaneously by way of an
antecubital or femoral vein and positioned in the pulmonary
artery. Pressures were measured with a Bell and Howell
transducer positioned at the mid-chest level with the patient
supine, and were displayed on a multichannel direct writing
Hewlett-Packard recorder. Right atrial and pulmonary artery
phasic, mean and occluded pressures were recorded. Pul-
monary wedge pressure was taken as occluded pulmonary
artery pressure or pulmonary artery diastolic pressure if this
did not differ from the occluded pressure by more than 4
mm Hg. These pressures were not interchanged in the same
patient for data analysis. Systemic blood pressure was mea-
sured by the standard cuff technique, heart rate and rhythm
were continuously recorded electrocardiographically and
cardiac output was measured by thermodilution in at least
triplicate using iced saline solution (4°C) with a carbon
dioxide-powered injector and an Edwards Laboratories car-
diac output computer. In three patients, the Swan-Ganz
catheter could not be maintained in satisfactory position in
the pulmonary artery, and cardiac output was measured by
the carbon dioxide rebreathing method, an indirect Fick
procedure previously validated by us in patients with heart
failure (8,9).
Exercise protocol. Control measurements of pressures,
heart rate and cardiac output at rest were obtained at 30
minute intervals until two successive determinations varied
by less than 10%. On completion of baseline measurements
at rest, patients performed upright bicycle exercise to symp-
tomatic maximum (dyspnea or fatigue without any other
limiting cause) using a Monark bicycle ergometer. During
exercise, hemodynamic variables were monitored and ex-
pired gas was collected for on-line measurement of oxygen
consumption, carbon dioxide production and ventilatory ex-
change ratio using techniques described in a previous study
(3,10). Exercise was begun at a work load of 150 kilopond-
meters (kpm) and increased by 150 kpm every 4 minutes
until exhaustion. The ventilatory exchange ratio is used to
indicate onset of lactate production and achievement of an-
aerobic threshold (II). By these criteria all patients achieved
anaerobic threshold on all exercise tests as indicated by a
significant increase in ventilatory exchange ratio.
Initiation of vasodilator drug therapy. On completion
of all baseline measurements, patients were continued in
the study if pulmonary wedge pressure was greater than 15
mm Hg at rest or greater than 20 mm Hg during exercise,
or if cardiac index at rest was not more than 2.5 liters/min
per m2 . Patients meeting these criteria were then given their
first dose of vasodilator drug or placebo being tested. Iso-
sorbide dinitrate was administered as a 40 mg oral dose to
eight patients, minoxidil as a 20 mg oral dose to eight
patients, captopril as a 25 mg oral dose to eight patients
and enalapril, a new angiotensin-converting enzyme inhib-
itor (12), was administered as a 5 or 10 mg oral dose to
eight patients. lsosorbide dinitrate and minoxidil were ad-
ministered in fixed doses, and hemodynamic measurements
at rest were repeated 90 minutes after giving isosorbide
dinitrate and 4 hour after the dose of minoxidil; these are
times of approximate peak effect based on our previous
experience with these agents (13,14). Captopril and ena-
lapril doses were titrated over 24 hours until pulmonary
wedge pressure decreased or cardiac index increased by
30%, or to a maximal dose of 150 mg of captopril and 20
mg of enalapril. In three patients the dose of captopril was
titrated to 25 mg, in four patients to 100 mg and in one
patient to 150 mg. Acute hemodynamic effects of captopril
were measured 2 hours after the last dose during titration.
In five patients the dose of enalapril was titrated to 10 mg
and in three patients to 20 mg. Acute hemodynamic effects
of enalapril were taken as those observed 4 hours after the
last dose during titration, based on our prior experience with
this agent (15). Placebo, identical in appearance to isosor-
bide dinitrate or minoxidil, was administered to IS patients
and hemodynamic values were measured I 1/2 to 4 hours
later.
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Maintenance drug therapy. After completion of base-
line evaluation, patients continued with the dose of vaso-
dilator drug tested. Isosorbide dinitrate was administered 40
mg four times daily; minoxidil as 20 mg twice daily; cap-
topril as 25 mg three times daily in three patients, 100 mg
three times daily in four patients and 150 mg three times
daily in one patient and enalapril was given as 10 mg twice
daily in five patients and 20 mg twice daily in three patients.
Placebo was administered four times daily in eight patients
and twice daily in seven. Study drugs and digoxin were
maintained constant throughout the follow-up period while
diuretic drugs were adjusted as needed. Patients were seen
regularly at I to 4 week intervals. Patients taking placebo,
minoxidil and isosorbide dinitrate were followed up for 3
months, those taking enalapril for 1 month and those taking
captopril for 2 to 5 months. At the end of the follow-up
period, patients returned to the laboratory for repeat rest
and exercise measurements using these same techniques.
Measurements were made at the same time after test drug
dosing as during the baseline study. During follow-up, one
patient taking minoxidil died from severe heart failure before
repeat studies could be completed. The 46 patients who
completed the follow-up period are discussed in this report.
Analysis of data. Cardiac index was calculated as car-
diac output divided by body surface area and expressed as
liters/min per m2 . Systemic vascular resistance was calcu-
lated as mean arterial pressure minus right atrial pressure
divided by cardiac output and expressed in arbitrary units.
Mean pUlmonary artery and wedge pressures were elec-
tronically integrated, whereas mean systemic arterial pres-
sure was calculated as diastolic pressure plus one-third of
the pulse pressure.
Statistical analysis was performed using standard for-
mulas for mean, standard deviation and linear regression.
Values before and after test drugs were compared by paired
t tests. Long-term response to therapy was assessed by changes
in exercise capacity. Correlation coefficients (r) between
long-term responses and baseline measurements were cal-
culated. Because of the large number of r values calculated,
the significance level for these was adjusted for the number
of tests performed, thus requiring a probability (p) value of
0.05 divided by the number of t tests (Bonferroni correc-
tion). In this manner, a p value less than 0.001 was required
for an r value to be significant.
The assignment of ~pecific agents to individual patients
was not by any prospective scheme but was largely arbitrary.
Most of the patients were undergoing baseline evaluation
before entering trials of long-term vasodilator therapy for
heart failure.
Results
Clinical classifications. The vasodilator-treated group
consisted of 31 men whose age (± standard deviation)
averaged 55.8 ± 8.1 years (range 40 to 72) (Table 1). The
cause of congestive heart failure was ischemic heart disease
Table 1. Baseline Comparison of Patients With Congestive Heart Failure Treated With Vasodilators or Placebo
Vasodilators Placebo p Value
Patients (no.) 31 15
Age (yr) 55.5 ± 8.1 57.3 ± 7.0 NS
Cause of heart failure
(% of patients)
Ischemic heart disease 55 60 NS
Primary myocardial disease 45 40 NS
Clinical class*
(% of patients)
II 29 20 NS
III 55 67 NS
IV 16 13 NS
Cardiothoracic ratio (%) 55.2 ± 7.1 57.0 ± 4.1 NS
Left ventricular diastolic 65.1 ± 10.5 67.1 ± 5.4 NS
dimension (mm)
Left ventricular ejection 28.7 ± 17.8 27.2 ± 15.0 NS
fraction (%)
Heart rate (beats/min) 77.5 ± 12.3 81.5 ± 13.9 NS
Mean arterial pressure (mm Hg) 90.2 ± 13.7 87.6 ± 10.1 NS
Pulmonary wedge pressure (mm Hg) 20.2 ± 9.2 22.6 ± 6.5 NS
Cardiac index (liters/min per m2) 2.36 ± 0.70 2.26 ± 0.52 NS
Systemic vascular resistance 21.1 ± 7.8 21.1 ± 5.4 NS
(units)
Duration of follow-up (mo) 2.4 ± 1.1 2.9 ± 0.2 NS
Values shown are mean ± I standard deviation. * = according to criteria of the New York Heart Association. NS = not significant; p = probability.
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in 17 patients and primary myocardial disease in 14 patients. did not meet hemodynamic criteria at rest had marked in-
All patients were symptomatic. New York Heart Associa- creases in pulmonary wedge pressure to greater than 20 mm
tion functional class II symptoms were present in 9 patients, Hg during exercise. Of the three patients without baseline
class III symptoms in 17 patients and class IV symptoms pulmonary wedge pressure measurements, two had a low
in 5 patients. cardiac index. The other patient (Patient 11) had a normal
Baseline cardiac dimensions and hemodynamic data of cardiac index at rest, but was included in the study because
these patients are shown in Table 2. All but eight patients of marked exercise intolerance and a very low (16%) left
had a cardiothoracic ratio greater than 50%. Of these eight ventricular ejection fraction at rest. The placebo-treated group,
patients, seven had a left ventricular ejection fraction below which was included because of the possibility of sponta-
40% and the remaining patient met the screening criterion neous changes in hemodynamic status or exercise capacity
of increased left ventricular diastolic dimension. The group during vasodilator administration, did not differ from the
as a whole had increased cardiothoracic ratio and left ven- vasodilator-treated group in any baseline characteristic (Ta-
tricular diastolic dimension with depressed left ventricular ble I).
ejection fraction indicative of left ventricular dysfunction. Hemodynamic drug responses. Initial and later follow-
Baseline hemodynamic measurements also indicated ab- up hemodynamic responses are summarized in Figure I.
normal left ventricular function with elevated pulmonary Mean arterial pressure decreased by an average of 10.0 ±
wedge pressure and low cardiac index. Four patients who 12.5 mm Hg (p < 0.00 I) after initial vasodilator doses and
Table 2. Baseline Characteristics of Patients With Chronic Left Ventricular Failure
Case Drug CTR LVOO LVEF HR MAP PWP CI SVR
1 IS 50 77 19 64 70 28 3.89 10
2 IS 44 56 39 80 105 9 1.87 31
3 IS 58 64 22 96 97 36 1.70 29
4 IS 63 80 103 17 1.86 26
5 IS 60 75 75 29 1.24 32
6 IS 57 74 24 97 87 30 1.54 29
7 IS 55 75 104 26 2.52 24
8 IS 52 84 95 26 1.83 22
9 M 51 52 71 65 119 9 3.81 13
10 M 49 56 35 76 104 6 3.01 20
II M 58 71 16 60 82 3.45 12
12 M 61 61 31 92 103 7 3.14 15
13 M 61 67 21 59 88 17 1.94 17
14 M 42 59 35 77 80 2.03 19
15 M 50 58 27 65 86 1.86 26
16 E 53 62 45 95 101 II 2.46 20
17 E 55 50 40 66 104 8 2.50 19
18 E 66 66 12 95 98 23 2.10 20
19 E 60 70 26 74 108 17 3.32 18
20 E 60 96 10 74 76 27 2.17 18
21 E 72 75 28 87 80 30 2.42 13
22 E 40 64 47 62 98 20 3.29 16
23 E 55 53 32 84 100 4 2.76 24
24 C 61 24 89 100 38 1.62 41
25 C 52 64 25 81 77 26 2.16 17
26 C 64 57 23 80 70 19 1.83 18
27 C 50 60 33 50 90 15 1.85 27
28 C 47 63 25 80 79 22 2.44 13
29 C 54 33 92 76 17 1.50 39
30 C 52 69 19 67 67 24 2.14 16
31 C 60 84 12 81 74 25 2.81 II
Mean 55.2 65.1 28.7 77.5 90.2 20.2 2.36 21.1
± SO 7.1 10.5 12.8 12.3 13.7 9.2 0.70 7.8
± SEM 1.3 2.1 2.5 2.2 2.5 1.7 0.13 1.4
C = captopril; CI = cardiac index (liters/min per m2); CTR = cardiothoracic ratio (%); E = enalapril; HR = heart rate (beats/min); IS = isosorbide
dinitrate; LVOD = left ventricular diastolic dimension (mm); LVEF = left ventricular ejection fraction (%); M = minoxidil; MAP = mean arterial
pressure (mm Hg); PWP = mean pulmonary wedge pressure (mm Hg); SD = standard deviation; SEM = standard error of the mean; SVR = systemic
vascular resistance (units).
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Figure 1. Hemodynamic responses to vasodilators
in patients with chronic left ventricular failure. C
= control; CI = cardiac index; I = initial response
after dose titration; L = late responses after I to 3
months; MAP = mean arterial pressure; PWP =
pulmonary wedge pressure; SVR = systemic vas-
cular resistance; * = p < 0.05; ** = P < 0.02;
*** = P < 0.01; **** = P < 0.001 (all p values
are compared with original baseline control values).
Solid circles and lines = mean ± standard error
of the mean for vasodilator-treated group. Open
circles and broken lines = mean ± standard error
of the mean for placebo-treated group.
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was still significantly decreased by 6.9 ± 11.0 mm Hg at
later follow-up (p < 0.01). Paralleling changes in blood
pressure, systemic vascular resistance decreased by 4.0 ±
5.9 units after initial vasodilator administration (p < 0.00 I),
and at a later follow-up study was still reduced by 4.5 ±
4.4 units (p < 0.001). Thus, the active test drugs did produce
immediate vasodilation that was sustained during long-term
treatment. There were no significant hemodynamic changes
observed any time after placebo administration.
Changes in pulmonary wedge pressure and cardiac index
reflected the known actions of the individual drugs tested.
For the entire group pulmonary wedge pressure decreased
initially by an average of 5.9 ± 7.4 mm Hg (p < 0.001),
and at follow-up study was insignificantly reduced by 3.3
± 8.7 mm Hg from baseline control levels. Cardiac index
increased by 0.28 ± 0.69 liters/min per m2 after initial
vasodilator administration (p < 0.05), and remained sig-
nificantly increased by 0.48 ± 0.89 liters/min per m2 at
follow-up (p < 0.02). Pulmonary wedge pressure decreased
by 7.5 ± 3.0 mm Hg after initial doses of isosorbide din-
itrate (p < 0.001), a predominant venodilator, and was
unchanged by the arterial dilator minoxidil. Enalapril, an
arterial and venous dilator, reduced pulmonary wedge pres-
sure slightly by 3.0 ± 7.5 mm Hg (not significant), and
captopril decreased it by 10.8 ± 8.7 mm Hg (p < 0.001).
Captopril-treated patients did not have pulmonary wedge
pressure measurements at later follow-up, probably ac-
counting for the insignificant reduction of wedge pressure
in the whole group of patients at follow-up. Cardiac index
increased significantly only after captopril and minoxidil
administration. Because blood pressure decreased signifi-
cantly (- 10.9 ± 12.0 mm Hg, p < 0.05), and cardiac
index increased after enalapril administration, systemic vas-
cular resistance was significantly reduced by 2.8 ± 2.4
units (p < 0.02). Thus, each test drug individually produced
significant hemodynamic changes of some type.
Vasodilator effect on exercise capacity. The effects of
long-term vasodilator administration on exercise capacity
are shown in Figure 2. Exercise duration increased by 1.8
± 3.5 minutes (p < 0.01) from a control value of 9.6 ±
5.2 minutes. This was equivalent to a 47% increase (p <
0.01). Maximal oxygen uptake at baseline study averaged
14.1 ± 5.6 mllmin per kg and increased by 2.9 ± 5.7
mllmin per kg (29%) during long-term vasodilator admin-
istration (p < 0.01). The average control value for maximal
oxygen uptake is markedly below normal for men of this
age and places these patients in our exercise class III (3).
In the placebo-treated group, exercise capacity was similar
at baseline and did not change during follow-up.
The relation between long-term responses, as indicated
by changes in maximal oxygen uptake, and initial hemo-
dynamic responses to vasodilator drugs are shown in Figure
3. Maximal oxygen uptake was chosen as the indicator for
long-term response because of its greater objectivity, es-
pecially when achievement of anaerobic threshold is doc-
umented. In our patients, exercise duration and maximal
oxygen uptake were closely correlated (r = 0.84, P <
0.001). There were no significant correlations between
changes in pulmonary wedge pressure, cardiac index or
systemic vascular resistance after initial vasodilator doses
and long-term changes in maximal oxygen uptake. Because
II patients required a change in diuretic therapy during
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follow-up and I of these also had a transient reduction in
minoxidil dosage, data were analyzed separately in the other
20 patients who had no changes in any of their medications
during the follow-up period. In these 20 patients, there was
still no significant correlation between changes in pulmonary
wedge pressure and in maximal oxygen uptake (r = 0.01),
or between changes in cardiac index and in maximal oxygen
uptake (r = 0.33). Likewise, initial changes in systemic
vascular resistance also failed to correlate significantly with
long-term changes in maximal oxygen uptake. Not only
were there no significant correlations between initial hemo-
dynamic effects of vasodilator drugs and long-term re-
sponses assessed by exercise capacity, the long-term hemo-
dynamic responses and changes in exercise capacity also
failed to correlate. The r values for long-term hemodynamic
responses and changes in maximal oxygen uptake were:
- 0.38 for pulmonary wedge pressure, - 0.07 for cardiac
index and - 0.23 for systemic vascular resistance. These
poor correlations between hemodynamic responses and
changes in exercise capacity were not altered when data
were analyzed using percent change instead of absolute
changes for all variables, as was done in our preliminary
report (16).
Comparison of individual vasodilator drugs. Although
individual vasodilator-treated SUbgroups were small, they
were analyzed individually. As previously stated, each vaso-
dilator produced some short-term hemodynamic effect. These
effects were sustained over time as a reduction in pulmonary
wedge pressure -7.8 ± 6.8 mm Hg (p < 0.02) and sys-
temic vascular resistance - 6.0 ± 4.7 units (p < 0.01) at
follow-up in isosorbide dinitrate-treated patients. At follow-
up, in the minoxidil-treated group, cardiac index was still
increased 1.04 ± 1.37 liters/min per m2 (p < 0.01) and
systemic vascular resistance was reduced - 5.6 ± 5.4 units
(p < 0.05). At follow-up in enalapril-treated patients, mean
arterial pressure and systemic vascular resistance were re-
duced (-9.3 ± 7.5 mm Hg [p < 0.01] and -2.0 ± 1.9
units [p < 0.02], respectively). Follow-up hemodynamic
measurements were not obtained in captopril-treated pa-
tients. Maximal oxygen consumption increased during treat-
ment with each vasodilator, except minoxidil, but there were
no significant correlations between any initial hemodynamic
effect and changes in exercise capacity in any individual
vasodilator-treated subgroup (Table 3).
Baseline cardiac performance, baseline exercise ca-
pacity and changes in vasodilator therapy. Because re-
sponsiveness to a therapeutic intervention could relate to
the severity of heart failure at baseline, we performed linear
regression analysis in an attempt to relate various baseline
characteristics of the patient group to exercise capacity at
baseline and to changes in exercise capacity at later follow-
up study (Table 4). Using the statistical criteria set forth by
us and requiring a p value less than 0.001, none of the r
values shown in the table achieved statistical significance.
These observations showing lack of correlation between
baseline hemodynamic characteristics and baseline exercise
capacity confirm our previous findings (3,4). The observed
lack of correlation between these same baseline variables
and long-term response further suggests that baseline as-
sessment of severity of heart failure based on hemodynamic
criteria is not very predictive of long-term therapeutic re-
sponses judged by changes in exercise tolerance. It is also
noteworthy that the baseline exercise capacity was also not
related to long-term changes in exercise capacity.
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Figure 3. Relation between acute hemodynamic effects of vaso-
dilators and long-tenn changes in exercise capacity in patients with
chronic left ventricular failure. C = captopril; CI = cardiac index;
E = enalapril; IS = isosorbide dinitrate; M = minoxidil; PWP
= pulmonary wedge pressure; SVR = systemic vascular resis-
tance. No r values are statistically significant. Values of r shown
are for all groups combined; no r values within individual groups
are significant.
Discussion
Selection of optimal vasodilator agent. Hemodynamic
measurements are commonly employed in the diagnosis and
management of patients with congestive heart failure. Such
measurements have been valuable in characterizing and
quantitating the effects of pharmacologic interventions, es-
pecially the site, duration and magnitude of action of vas-
odilator drugs (2,17). Because hemodynamic abnormalities
are usually present in patients with congestive heart failure,
it has been assumed that pharmacologic correction of these
abnormalities relates to long-term therapeutic responses.
Therefore, it has been advocated that selection of vasodilator
agents be tailored to suit the individual hemodynamic profile
(6,7,18,19). Patients with symptoms primarily of pulmo-
nary vascular congestion might benefit more from drugs with
predominant preload-reducing effects, such as nitrates. In
contrast, symptoms of low cardiac output might be better
treated with primary arterial dilating agents, such as hy-
dralazine or minoxidiL which more effectively increase car-
diac output. Patients with symptoms attributable to both low
cardiac output and pulmonary vascular congestion should
do better with agents that dilate both arteries and veins, such
as prazosin, hydralazine plus nitrate, or angiotensin-con-
verting enzyme inhibitors. In addition to using hemody-
namic measurements to select a vasodilator, it has also been
common practice to titrate a chosen agent to a dose that
produces a desired hemodynamic response (6,20-22) .
Although these practices have been recommended, actual
experience has shown no correlation between acute hemo-
dynamic effects and long-term clinical responses (23-25).
Earlier studies (23) using hydralazine titrated to achieve an
"optimal" short-term increase in cardiac output found that
long-term outcomes were variable and unrelated to the he-
modynamically titrated doses of hydralazine. Another study
(24) using hydralazine and nitrates in combination also found
a poor relation between long-term clinical response and the
magnitude of initial hemodynamic responses. The authors
observed, however, that lack of any short-term response
was associated with a poor long-term clinical response. Thus,
it appears that some quantifiable response is desirable but
the magnitude of that response is not predictive of later
outcome. Therefore, selection of any dose thought to be
hemodynamically effective should be sufficient for insti-
tution of long-term therapy .
Relation of short- and long-term hemodynamic effects
to clinical efficacy. The earlier studies just cited were in-
tended primarily to assess long-term efficacy of vasodilators
in heart failure, and not to examine the relation between
baseline hemodynamic evaluation and long-term response.
Furthermore, they all used hydralazine, which has been
shown to be no more effective than placebo in altering
exercise capacity during long-term administration to patients
with chronic left ventricular failure (26). Our study repre-
sents an initial attempt to relate baseline hemodynamic sta-
tus, as well as short- and long-term hemodynamic effects
of vasodilators, to long-term clinical efficacy in patients with
chronic left ventricular failure. Furthermore. we used a va-
riety of vasodilator drugs with primarily venous, primarily
arterial or balanced arterial and venous dilating ability. Be-
cause long-term clinical response is difficult to assess, we
chose the objective measurement of exercise capacity as an
indicator of symptomatic status and clinical efficacy. Such
testing has commonly been used to demonstrate clinical
efficacy of vasodilators in patients with heart failure
(21,22,27). We were unable to show any significant cor-
relations between baseline hemodynamic values. initial
hemodynamic responses or late hemodynamic responses to
the various vasodilators tested and long-term effects on ex-
ercise capacity. Our results were probably not related to
ineffective doses, as each of the drugs tested produced some
acute beneficial hemodynamic response. Furthermore. vas-
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Table 3. Relation Between Acute Hemodynamic Effects of Individual Vasodilators and Long-
Term Effects on Exercise Capacity in Patients With Heart Failure
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Change in maximal oxygen
uptake (mlimin per kg)
Coefficient of correlation
between change in maximal
oxygen uptake and initial
change in:
Pulmonary wedge pressure
Cardiac index
Systemic vascular resistance
Isosorbide
Dinitrate
6.9 ± 2.4t
0.45
0.57
-0.42
Minoxidil
-0.9 ± 4.3
0.33
-0.36
0.54
Enalapril
1.6 ± 3.5*
-0.04
-0.04
0.33
Captopril
3.3 ± 4.7*
-0.12
-0.47
-0.27
Values shown = mean ± I standard deviation. * = p < 0.1; t = P < 0.05. No coefficients of correlation
are statistically significant (all p > 0.05).
odilator responses in the group were sustained as systemic
vascular resistance was still significantly reduced at late
follow-up. Changes in pulmonary wedge pressure and car-
diac output varied according to the specific vasodilator drug
employed, as expected.
Validity of hemodynamic effects and changes in ex-
ercise capacity. The overall effects of vasodilators on
hemodynamics and exercise capacity in our patients might
be considered modest, but they are consistent with previous
reports (28) and probably reflect varying responses to in-
dividual agents. Thus, the lack of effect of minoxidil and
the modest effect of enalapril on pulmonary wedge pressure
combined to limit the overall effect on wedge pressure. It
is known that minoxidil has little or no effect on pulmonary
artery pressures, and the observed responses to enalapril are
consistent with those reported by others (14,29). Likewise,
the overall increase in cardiac output was limited by the
modest effects of isosorbide dinitrate and enalapril, again
consistent with previous reports (2,15,29). In this regard,
although captopril consistently increases cardiac output, the
magnitude of this change has been relatively modest in
patients with heart failure (2,22,28). The observed changes
in exercise duration and maximal oxygen uptake for the
group as a whole were also within the range previously
reported (21,26-28). Effects on exercise capacity were lim-
ited by the failure of minoxidil to increase maximal oxygen
uptake, despite producing sustained vasodilation. This re-
sponse to minoxidil is similar to that observed during admin-
istration of hydralazine, a similar arterial dilator, in heart
failure (26).
Despite these considerations, we did not observe signif-
icant correlations between hemodynamic effects and changes
in exercise capacity within any individual vasodilator-treated
subgroup. Therefore, we believe that our overall results are
valid. Furthermore, the changes in hemodynamics and ex-
ercise capacity that occurred during vasodilator treatment
are thought to be significant not only on a statistical basis,
but also because these variables remained unchanged during
placebo administration to similar patients.
Correlation between baseline patient characterization
and changes in exercise capacity. The present results con-
firm our previous observation (34) that baseline indicators
of severity of heart failure, including cardiac dimensions,
hemodynamics and left ventricular ejection fraction, do not
correlate with objectively measured exercise capacity at that
time. These observations have now been extended to show
a further lack of correlation between these same baseline
patient characteristics and changes in exercise capacity dur-
Table 4. Relation of Baseline Cardiac Performance to Baseline Exercise Capacity and Changes
in Exercise Capacity During Vasodilator Treatment in Patients With Chronic Heart Failure
Baseline Characteristic
Cardiothoracic ratio
Left ventricular diastolic dimension
Left ventricular ejection fraction
Pulmonary wedge pressure
Cardiac index
Systemic vascular resistance
Maximal oxygen uptake
Coefficient of Correlation
With Baseline Exercise Capacity
-0.47
-0.26
0.42
-0.41
0.51
0.38
Coefficient of Correlation
With Change in Exercise
Capacity
0.34
0.41
-0.45
0.26
-0.48
0.42
-0.36
No r values achieved statistical significance (p < 0.001).
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ing long-term treatment. In addition, the symptomatic status
of patients at baseline study, assessed by exercise testing,
is unrelated to long-term changes in exercise capacity during
treatment. Thus, baseline assessment of severity of symp-
toms or of degree of cardiac dysfunction does not appear
to relate to long-term changes in functional capacity of pa-
tients with chronic left ventricular failure during therapeutic
trials of vasodilator drugs. These results should be applied
only to patients with chronic heart failure as ample clinical
experience suggests that immediate hemodynamic improve-
ment is frequently associated with relief of symptoms in
patients with acute left ventricular failure (30-34). In fact,
patients with more severe baseline hemodynamic abnor-
malities appear to respond better to vasodilator administra-
tion in the setting of acute heart failure (2,33,34).
Clinical implications. The present results are clinically
relevant as they raise questions concerning the need to hos-
pitalize patients for costly and prolonged invasive hemo-
dynamic studies to initiate long-term vasodilator therapy for
chronic congestive heart failure. It is no longer our practice
to routinely evaluate hemodynamic status at baseline. It is
essential, however, that patients be started on a presumed
hemodyna.mically effective dose of one or more vasodila-
tors. In the vast majority of patients, the effective dose range
for most vasodilators is well known (2,17,22,27), and it is
only necessary that patients be started on these doses without
quantitating hemodynamic responses. Hemodynamic mea-
surements may still be needed in some situations. They may
be required to confirm the diagnosis of heart failure because
the symptoms of dyspnea and fatigue are very nonspecific
and noninvasive measurements of cardiac size and function
may be inconclusive. Measurement of left ventricular filling
pressure and cardiac output at rest and during exercise may
definitively establish the diagnosis of heart failure, Hemo-
dynamic measurements may also be useful to look for evi-
dence of resistance or tolerance to drugs when therapeutic
response has been unsatisfactory (35,36),
We do not wish to suggest that hemodynamic measure-
ments have no value in assessing long-term outcome in
patients with chronic congestive heart failure. This study
shows only that such measurements do not relate to long-
term outcome as assessed by exercise capacity, which pre-
sumably reflects symptomatic status of patients. Most im-
portantly, there is no evidence to suggest that measured
exercise capacity relates to long-term prognosis, that is,
mortality and morbidity complicating the course of heart
failure. It may not, therefore, be satisfactory to rely only
on results of exercise testing as a means for establishing
efficacy of treatment. Survival of patients with congestive
heart failure is related to measurements of left ventricular
function and hemodynamics, survival being reduced as these
indexes worsen (37,38). Therefore, such measurements are
important in evaluating overall efficacy of therapeutic in-
terventions in heart failure and can justifiably be included
in the setting of clinical investigation. However, the results
of our study suggest that it is not necessary in clinical prac-
tice to routinely perform expensive invasive hemodynamic
studies to initiate vasodilator therapy in patients with
congestive heart failure. Physicians should select those agents
that are not contraindicated and with which they are most
familiar.
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